Brain metastases: still an 'orphan' disease?

Area of Science:

• Neuro-oncology
• Translational Cancer Research
• Clinical Trial Design

Background:

• Brain metastases from systemic cancer are linked to poor patient prognosis.
• Historically, chemotherapy clinical trials have largely excluded patients with metastatic disease, limiting research.
• Previous clinical and basic research in this area has been limited.

Purpose of the Study:

• To review recent advancements in the management of brain metastases.
• To highlight emerging treatment strategies and their potential impact.
• To emphasize the need for focused investigation into chemotherapy's role.

Main Methods:

• Review of recent developments in clinical trial design, including recursive partitioning analysis.
• Integration of new treatment strategies in neurosurgery and radiotherapy.
• Analysis of recent advances in understanding the biology of brain metastases.

Main Results:

• Recent developments indicate a shift in the approach to managing brain metastases.
• New treatment strategies in neurosurgery and radiotherapy are complementing clinical trial design.
• Advances in understanding metastasis biology are paving the way for next-generation therapies.

Conclusions:

• The management of brain metastases is evolving with improved clinical trial designs and treatment modalities.
• Targeted therapies based on the specific biology of brain metastases are anticipated.
• Further focused research is crucial to optimize chemotherapy's role in treating brain metastases.